# General Proximity

**Canonical:** https://apis.io/providers/generalproximity/  
**Website:** https://www.generalproximity.bio  
**APIs profiled:** 0

General Proximity is a biotechnology company pioneering next-generation "proximity medicines" that control biological processes by inducing proximity between molecular targets. Its multi-target OMNITAC platform is used to discover and advance novel therapeutics, including an oncology collaboration with Daiichi Sankyo. The company is backed by investors including Felicis and Y Combinator, and has drawn investment from Freemind and Daewoong Pharmaceutical. This is a company profile in the API Evangelist network; General Proximity is a drug-discovery company and does not publish a public API, developer portal, or machine-readable API artifacts at this time.

## Kin Score — 2.7 / 100 (minimal)

Scored 2026-08-20 under rubric 0.12.0. Trend: flat (+0.0 from 2.7).

| Facet | Score |
|---|---|
| Discoverability | 50.0 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 2.4 |
| Commercial Clarity | 0.0 |
| Access Clarity | 0.0 |

Regulatory layer — **Health**: 0.0 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Access

Unknown — onboarding: unknown, pricing: unknown, trial: no (confidence: low).

## Tags

Company, Biotechnology, Pharmaceuticals, Drug Discovery, Proximity Medicines, Oncology, Therapeutics, Life Sciences

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/generalproximity/). Scores are computed from the provider's own public artifacts under a published rubric.